Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort
| Autor: | Shalem Modi, Henna Cederberg, Nagendra Yaluri, Johanna Kuusisto, Markku Laakso, Alena Stančáková |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Glucose tolerance test
medicine.medical_specialty education.field_of_study Statin medicine.diagnostic_test medicine.drug_class business.industry Endocrinology Diabetes and Metabolism Population nutritional and metabolic diseases Type 2 diabetes medicine.disease Insulin resistance Endocrinology Simvastatin Internal medicine Diabetes mellitus Internal Medicine medicine Metabolic syndrome business education medicine.drug |
| Zdroj: | Diabetologia. 58:1109-1117 |
| ISSN: | 1432-0428 0012-186X |
| DOI: | 10.1007/s00125-015-3528-5 |
| Popis: | Aims/hypothesis The aim of this work was to investigate the mechanisms underlying the risk of type 2 diabetes associated with statin treatment in the population-based Metabolic Syndrome in Men (METSIM) cohort. Methods A total of 8,749 non-diabetic participants, aged 45–73 years, were followed up for 5.9 years. New diabetes was diagnosed in 625 men by means of an OGTT, HbA1c ≥6.5% (48 mmol/mol) orglucose-lowering medicationstarted during the follow-up. Insulin sensitivity and secretion were evaluated with OGTT-derived indices. Results Participants on statin treatment (N=2,142) had a4 6% increased risk of type 2 diabetes (adjusted HR 1.46 [95% CI 1.22, 1.74]). The risk was dose dependent for simvastatin and atorvastatin. Statin treatment significantly increased 2 h glucose (2hPG) and glucose AUC of anOGTTat follow-up,with a nominally significant increase in fasting plasma glucose (FPG). Insulin sensitivity was decreased by 24% and insulin secretion by 12% in individuals on statin treatment (at FPG and 2hPG |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink